Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701110 | 0.95 | SRD5A2 (0.57) | PKMNR4A2NR4A1NR4A3GSTP1 | |
| SCHEMBL16561436 | 0.86 | CA12 (0.53) | GSTP1CA12CA1CA2CA4 | |
| SCHEMBL12517362 | 0.86 | CYP19A1 (0.59) | GSTP1CA12CA1CA2CA4 | |
| SCHEMBL11746611 | 0.85 | CA12 (0.59) | PKMGSTP1CA12CA1CA2 | |
| SCHEMBL18223888 | 0.84 | KDM4E (0.56) | GSTP1CA12CA1CA4CA9 | |
| SCHEMBL22495331 | 0.84 | PKM (0.62) | PKMNR4A2NR4A1NR4A3PLA2G4B | |
| SCHEMBL11529553 | 0.84 | GAA (0.60) | MAPK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9718528 | 0.83 | CA12 (0.50) | GSTP1CA12CA1CA2CA4 | |
| SCHEMBL20273256 | 0.83 | PARP10 (0.59) | GSTP1CA12CA1CA2CA4 | |
| SCHEMBL9155792 | 0.83 | L3MBTL1 (0.61) | GSTP1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989427-B | Polytriazole resin toughened by propargyl polypropylene glycol, preparation method and application thereof | 华东理工大学 | 2023-11-14 | — | — | CN | claimed |
| CN-115073365-A | Probe for modifying protein lysine residue, preparation method thereof and modified biosensor thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2022-09-20 | — | — | CN | claimed |
| CN-114989427-A | Polytriazole resin toughened by propargyl polypropylene glycol, and preparation method and application thereof | 华东理工大学 | 2022-09-02 | — | — | CN | claimed |
| CN-109970987-B | MOF material, nano drug-loaded material, drug composition and application thereof | 中国医学科学院放射医学研究所 | 2021-09-17 | — | — | CN | claimed |
| JP-1233259-A | — | — | None | — | — | JP | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | LYCIA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025041533-A1 | SEMICONDUCTOR SUBSTRATE PRODUCTION METHOD AND FILM-FORMING COMPOSITION | JSR株式会社 | 2025-02-27 | — | — | WO | disclosed |
| WO-2024086633-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF DM1 PROTEIN KINASE (DMPK) COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-114989427-B | Polytriazole resin toughened by propargyl polypropylene glycol, preparation method and application thereof | 华东理工大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-113912532-B | Probe for protein lysine residue chemical modification and preparation method thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2023-09-08 | — | — | CN | disclosed |
| US-4654344-A | ALSO AFFECT BLOOD PRESSURE AND MYOCARDIAL CONTRACTIONS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-03-31 | — | — | US | disclosed |
| EP-0093951-B1 | 2-ARYL-TETRAAZAINDENES | MERCK PATENT GmbH (DE) | 1986-10-29 | — | — | EP | disclosed |
| US-4616090-A | 2-arylimidazopyridines intermediates | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
| US-4575505-A | Pharmaceutical compositions containing 2-aryltetraazaindenes for treating ulcers or cardiac insufficiency or blood pressure abnormalities | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-03-11 | — | — | US | disclosed |
| US-4477454-A | INDOTROPIC AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-16 | — | — | US | disclosed |
| EP-0093951-A2 | 2-Aryl-tetraazaindenes | MERCK PATENT GmbH (DE) | 1983-11-16 | — | — | EP | disclosed |
| EP-0072926-A1 | 2-Arylimidazopyridines | MERCK PATENT GmbH (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | ASGR1, LAMP2, FCGR2A | PKM 3998/4885NR4A2 2558/4885NR4A1 3562/4885 |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | PKM 3998/4885NR4A2 2558/4885NR4A1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.